GGrantIndex
← Search

Winship Cancer Institute Cancer Center Support Grant

$72,918P30FY2018CANIH

Emory University, Atlanta GA

Investigators

Linked publications, trials & patents

Trial NCT07405476Trial NCT07213154Trial NCT07174570Trial NCT07155317Trial NCT07150546Trial NCT07140679Trial NCT07112690Trial NCT07104240Trial NCT07101445Trial NCT06914999Trial NCT06868433Trial NCT06865768Trial NCT06799481Trial NCT06760507Trial NCT06731270Trial NCT06709534Trial NCT06708351Trial NCT06674863Trial NCT06662058Trial NCT06650579Trial NCT06636734Trial NCT06595160Trial NCT06583148Trial NCT06541158Trial NCT06534125Trial NCT06495125Trial NCT06492759Trial NCT06492070Trial NCT06423326Trial NCT06328699Trial NCT06328686Trial NCT06324240Trial NCT06254911Trial NCT06132685Trial NCT06105918Trial NCT06008730Trial NCT06006013Trial NCT05998135Trial NCT05877859Trial NCT05873608Trial NCT05798507Trial NCT05779943Trial NCT05756569Trial NCT05733351Trial NCT05526872Trial NCT05514912Trial NCT05513859Trial NCT05506982Trial NCT05493566Trial NCT05488145Trial NCT05464810Trial NCT05391750Trial NCT05387915Trial NCT05368428Trial NCT05346692Trial NCT05341349Trial NCT05320406Trial NCT05315687Trial NCT05310448Trial NCT05274763Trial NCT05250895Trial NCT05245682Trial NCT05244239Trial NCT05208307Trial NCT05204160Trial NCT05103904Trial NCT05091866Trial NCT05086731Trial NCT05039073Trial NCT05017610Trial NCT04908709Trial NCT04895592Trial NCT04890236Trial NCT04883437Trial NCT04878029Trial NCT04848519Trial NCT04776395Trial NCT04762199Trial NCT04754945Trial NCT04750473Trial NCT04731376Trial NCT04725903Trial NCT04676087Trial NCT04590664Trial NCT04585724Trial NCT04524702Trial NCT04483206Trial NCT04433949Trial NCT04428671Trial NCT04393350Trial NCT04366791Trial NCT04361552Trial NCT04352205Trial NCT04348292Trial NCT04340882Trial NCT04278118Trial NCT04276194Trial NCT04262869Trial NCT04191421Trial NCT04144127

Abstract

PROJECT SUMMARY/ABSTRACT The Winship Cancer Institute of Emory University (Winship) is the only NCI-designated cancer center in Georgia, which is now the eighth most populous state and has the largest land area among states east of the Mississippi River. As the main tertiary cancer care and cancer research institution in the state, Winship has committed its four research programs as supported by its six shared resources to address the specific challenges associated with the cancer burden in Georgia. These challenges include: high tobacco usage and incidence of tobacco- related cancers; high proportion of cancer patients who are African American or black and/or have significant cancer disparity issues in their care, prognosis, and/or outcome; and low health literacy levels. Winship's mission is to lessen the burden of cancer for the citizens of Georgia, its primary catchment area. This will be accomplished by: (1) seeking greater insights into the molecular, genetic, and epigenetic basis of cancer; (2) discovering new knowledge that drives improvements in cancer detection, prevention, and/or therapy; (3) developing or defining novel therapeutic targets and/or agents as a pathway to better cancer therapies; and (4) studying and implementing population-based strategies to lessen the cancer burden in the state. The 164 Winship core members are actively engaged in one of four Winship research programs, all of which have a strong emphasis on transdisciplinary research: Cancer Cell Biology, Cancer Genetics and Epigenetics, Cancer Prevention and Control, and Discovery and Developmental Therapeutics. Winship's members are supported by six shared resources: Biostatistics and Bioinformatics Shared Resource, Cancer Animal Models Shared Resource, Cancer Tissue and Pathology Shared Resource, Emory Integrated Genomics Shared Resource, Emory Integrated Proteomics Shared Resource, and the Integrated Imaging Shared Resource; and two developing shared resources: Winship Research Informatics and Intervention Development, Dissemination, and Implementation Developing Shared Resources. Winship members are currently supported by $84.8M in total research funding (as of 3/31/2016) awarded via Emory University. Winship members Curran and Bruner serve as PIs on two NCI awards to the NRG Oncology Foundation for a total of $25.6M in support of clinical research infrastructure. Patient enrollment in Winship's interventional and non-interventional trials continues to increase, especially among patients from under-represented minority groups, and these activities have contributed to the FDA- approval of several novel anti-cancer agents during the present funding period. Winship has outstanding institutional commitment, with more than $200 million in institutional support committed over the next five years, a level almost twice that committed in 2011. Winship enjoys the same reporting line and organizational position as Emory's schools of medicine, public health, and nursing. Winship is uniquely positioned to apply its scientific strengths, outstanding membership, robust infrastructure, strong institutional support, and comprehensive training programs to fulfill its mission of lessening the burden of cancer on the state of Georgia and beyond.

View original record on NIH RePORTER →